Latest Conference Articles

Watch Dr. Wendy Baer, from Winship Cancer Institute at Emory University, discuss psychosocial issues, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Emily Huskey, from the Winship Cancer Institute of Emory University, discuss diet and exercise, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kimberly Curseen, Dr. Anna Bausum, Dr. Kevin Kalinsky and Alyncia Mason answer questions about additional care, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kevin Kalinsky, from Winship Cancer Institute of Emory University, discuss joining clinical trials, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Anna Bausum, Winship Cancer Institute at Emroy University, discuss alternative medicine, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Kimberly Curseen, from Winship Cancer Institute of Emory University, discuss supportive care, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Suchita Pakkala, Dr. Jane Meisel, Dr. Keerthi Gogineni and Kelly Shanahan discuss updates in disease management during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Suchita Pakkala, from Emory University School of Medicine, discuss estrogen receptor-positive disease, during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Jeremie Calais, Dr. Tian Zhang, Dr. Landon C. Brown and Jim Rosenfield answer questions about novel agents and strategies during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.